Core Viewpoint - Senyi Intelligent has submitted its prospectus to the Hong Kong Stock Exchange, planning to list on the main board, positioning itself as a leading AI medical technology company with comprehensive solutions from L1 to L4 levels in the global AI medical industry [3][4]. Group 1: Company Overview - Senyi Intelligent is recognized as the only company in the global AI medical sector that offers solutions covering L1 to L4 levels, showcasing its full-stack technology development capabilities from data infrastructure to application layer algorithms and software [7][8]. - The company has been deeply engaged in the Chinese healthcare sector for many years, primarily serving hospitals and medical groups, maintaining a leading position in this niche market [8]. Group 2: Market Position - According to a report by Zhaoshang Consulting, Senyi Intelligent is the largest hospital AI medical solution provider in China based on hospital revenue projections for 2024, and it ranks as the fourth largest provider globally [9][10]. - As of June 30, 2025, Senyi Intelligent has served over 750 hospitals, including more than 400 large hospitals [10]. Group 3: Financial Performance - For the six months ending June 30, 2025, Senyi Intelligent reported revenue of approximately 112 million RMB, representing a year-on-year growth of about 23.3%. The net loss attributable to the parent company was approximately 91.87 million RMB, narrowing by about 5.7% year-on-year [3][12][13]. Group 4: Fundraising Purpose - The net proceeds from the IPO are intended for enhancing research and innovation capabilities, improving existing products and solutions, boosting commercialization efforts and establishing a global channel network, acquiring synergistic companies such as medical device manufacturers, and for working capital and other general corporate purposes [4][5]. Group 5: Technological Capabilities - Senyi Intelligent's solutions have executed over 23 million assessments monthly on average, supporting disease risk assessments for approximately 37 million patients and establishing over 1,600 specialized disease databases and research projects [11].

Core Viewpoint - The company, Shanghai Senyi Medical Technology Co., Ltd., has submitted a listing application to the Hong Kong Stock Exchange, positioning itself as a leading AI medical technology firm with comprehensive solutions from L1 to L4 levels in the global AI medical industry [1] Group 1: Company Overview - The company is recognized as the largest hospital AI medical solution provider in China and the fourth largest globally based on projected 2024 revenue [1] - As of June 30, 2025, the company has served over 750 hospitals, including more than 400 large hospitals [1] - The company aims to enhance public health, optimize patient care quality, improve clinical decision-making accuracy, and promote medical innovation [1] Group 2: Technology and Solutions - The company has developed an AI solution matrix centered around its core technology, Synapse, effectively integrating real-world medical needs with AI and large language model technologies [2] - The company has empowered over 800 clients, including hospitals and health regulatory bodies, with its solutions [2] - It has launched the world's first AI-led clinic pilot in Saudi Arabia, contributing to the advancement of the AI medical industry [2] Group 3: Financial Performance - The company has shown strong revenue growth, with client numbers increasing from 121 in 2022 to 244 in 2024, and revenue rising from RMB 143.7 million in 2022 to RMB 291.9 million in 2024, marking a 66.3% and 22.1% increase respectively [3] - For the six months ending June 30, 2025, revenue increased by 23.3% to RMB 112.3 million compared to the same period in the previous year [3] - The company recorded operating losses that decreased from RMB 232.5 million in 2022 to RMB 20.7 million in the six months ending June 30, 2025 [3] Group 4: Research and Development - The company's R&D team consists of 137 employees, with an average of eight years of experience, primarily located in Shanghai, Hangzhou, and Changchun [4] - R&D costs have decreased from RMB 135.9 million in 2022 to RMB 22.3 million in the six months ending June 30, 2025, representing a significant reduction in percentage of total revenue from 94.6% to 19.8% [4] - The funds raised from the listing will be allocated to enhancing R&D capabilities, upgrading existing products, improving commercialization, and potential acquisitions [4]